Skip to main content
TipRanks
Go Ultimate75% OFF

FunPep Company Limited (4881) AI Stock Analysis

0 Followers
JP:4881

FunPep Company Limited

(TSE/TYO:4881)

Select Model
Rating:44Neutral
Price Target:JPY 40.00â–²(2.56% Upside)
Action:reiterated
Date:10/29/26

Weak financial performance from severe losses and cash burn is the primary factor lowering the score, with bearish technical signals adding downward pressure and neutral valuation providing minimal offset.

Positive Factors
Debt-Free Balance SheetA debt-free balance sheet reduces refinancing pressure and avoids mandatory interest obligations, giving the company greater flexibility to allocate resources toward operations and development. This financial structure is particularly useful for an early-stage biotech facing uncertain revenue timing.
Negative Factors
Severe Revenue DeclineThe sharp 2025 revenue collapse indicates substantial instability in the company’s commercial performance and makes near-term revenue visibility weak. Such a decline can reduce operating leverage, constrain reinvestment capacity, and make recovery dependent on successfully rebuilding demand or product activity.

FunPep Company Limited (4881) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%60%JP:4881-54.65%EWJ+16.02%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 2.03B
Dividend Yield
―
Average Volume (3M)
191.60K
Price to Earnings (P/E)
-1.1
Beta (1Y)
0.75
Revenue Growth
-27.93%
EPS Growth
22.36%
Country
Japan
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

FunPep Company Limited Business Overview & Revenue Model

Company Description

FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-...

FunPep Company Limited Financial Statement Overview

Summary

Drastic revenue decline, worsening net losses, and persistent negative cash flows indicate weak financial health, partially offset by zero debt providing balance sheet stability.

Income Statement

10Very Negative

Balance Sheet

60Neutral

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.12M314.00K6.13M530.00K1.07M126.87M
Gross Profit-20.36M-41.58M-37.86M-43.03M-12.84M125.12M
EBITDA-1.26B-1.61B-859.23M-950.54M-1.16B-743.67M
Net Income-1.58B-1.91B-889.09M-933.42M-1.17B-682.26M
Balance Sheet
Total Assets2.11B1.98B3.11B2.49B2.99B3.36B
Cash, Cash Equivalents and Short-Term Investments1.89B1.77B2.35B1.79B2.25B3.01B
Total Debt000000
Total Liabilities433.93M516.73M566.27M192.61M298.11M188.67M
Stockholders Equity1.68B1.46B2.55B2.30B2.69B3.18B
Cash Flow
Free Cash Flow0-1.39B-537.60M-989.87M-1.07B-892.79M
Operating Cash Flow0-1.39B-536.74M-988.82M-1.05B-887.47M
Investing Cash Flow0-993.00K-30.83M-1.05M-19.14M-4.75M
Financing Cash Flow0810.93M1.12B537.81M245.13M282.68M

FunPep Company Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price39.00

Price Trends

50DMA45.40Negative
100DMA51.61Negative
200DMA66.12Negative

Market Momentum

MACD-1.75Negative
RSI36.83Neutral
STOCH66.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4881, the sentiment is Negative. The current price of 39.00 is below the 20-day moving average (MA) of 40.70, below the 50-day MA of 45.40, and below the 200-day MA of 66.12, indicating a bearish trend. The MACD of -1.75 indicates Negative momentum. The RSI at 36.83 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4881.

FunPep Company Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4881 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4570JP:457081OutperformJPY 8.46B22.61―0.66%7.10%17.17%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:2183JP:218350NeutralJPY 4.36B-1.15―4.15%-23.55%-205.65%
JP:4587JP:458748NeutralJPY 141.38B-48.49-5.85%―14.25%50.07%
JP:177AJP:177A45NeutralJPY 3.34B-113.15―1.53%-15.78%-104.11%
JP:4881JP:488144NeutralJPY 1.98B-1.13――-27.93%22.36%
JP:4571JP:457141NeutralJPY 6.19B-4.33-39.57%―48.92%-46.91%

* Healthcare Sector Average

Performance Comparison

0%100%200%JP:4881JP:4587JP:4571JP:177AJP:2183JP:4570Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4881 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4881FunPep Company Limited39.00-49.00-55.68%
JP:4587Peptidream 1089.00-587.00-35.02%
JP:4571NanoCarrier Co., Ltd.68.00-81.00-54.36%
JP:177AKohjin Bio Co.,Ltd.654.00-871.13-57.12%
JP:2183Linical Co., Ltd.193.00-98.98-33.90%
JP:4570Immuno-Biological Laboratories Co., Ltd.908.00-88.73-8.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 22, 2026